Advanced CRC is typically treated with monoclonal antibodies targeting epidermal growth factor receptor (EGFR), such as cetuximab or panitumumab, used alone or in combination with standard chemotherapy, but CRC patients harboring KRAS mutations do not respond to the antibody-based anti-EGFR treatment [4]. Here, EGFR is linked to colorectal carcinoma.